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ABSTRACT 
 
ELIZABETH L. CAMPBELL : A Cellular Comparison of Bone Inductive Properties of 
Trabecular Metal vs Titanium in Healthy and Osteopenia Subjects. 
(Under the direction of Thiago Morelli, Steven Offenbacher and Antonio Moretti) 
 In	this	study,	we	examined	the	histologic	healing	associated	with	initial	osseous	healing	comparing	trabecular	metal	vs.	standard	titanium	in	healthy	and	osteopenia/osteoporosis	subjects.	We	proposed	to	add	to	this	body	of	knowledge	 in	two	major	ways.	 First,	 we	 identified	 the	 temporal	 differences	 in	 cellular	recruitment	 and	activation	during	early	healing	and	early	osteogenesis,	and	the	bone	to	implant	contact	(BIC).	This	was	done	by	placing	test	cylinders	(approx.	2.9-3	x	5	mm)	using	 standard	 titanium	 or	 trabecular	metal.	Both	total	BIC	and	BIC	percentage	was	calculated	for	both	trabecular	and	titanium	cylinders	harvested	4	weeks	after	placement.	Secondly,	we	recognized	that	osseous	 healing	 can	 vary	 considerably	 in	the	 face	 of	 chronic	 health	 problems	 including	 osteopenia/ osteoporosis.	This	chronic	condition	is	known	to	 impair	bone	repair	and	osseous	regeneration.		The	use	of	trabecular	metal	may	have	the	strategic	advantage	of	demonstrating	superior	osseous	healing	in	these	compromised	individuals	as	compared	to	titanium.	This	project	was	designed	to	examine	the	 differences	 in	 the	 histologic	 BIC,	 not	 only	comparing	 trabecular	metal	 to	 titanium,	 but	 also	to	examine	these	differences	in	subjects	with	this	osseous	metabolic	compromising	condition.	
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CHAPTER 1: OSTEOPOROSIS/OSTEOPENIA, BONE AND TISSUE 
ENGINEERING AND THE ROLE OF DENTAL IMPLANTS IN AFFECTED 
PATIENTS 
 
Introduction 
 Osteoporosis is a debilitating metabolic bone disease that is a major health condition 
that affects approximately 75 million people in the US, Europe and Japan(1).  Ten million are 
affected in the U.S. alone, and by the year 2025 it is predicted that a 50% increase in 
prevalence will be seen due to the contribution of the aging population(2).  It is defined by 
the World Health Organization (WHO) as a bone density 2.5 SDs below the mean for young 
adult women(3).   Osteoporosis leads to an increased incidence of fracture, most notably hip 
fractures; leading to an increased mortality and morbidity(3).  In patients with hip fractures, 1 
in 5 die, while of the total number with osteoporotic related hip fractures, 1/3 require nursing 
home placement because they are functionally dependent(3).  These fractures trigger 
increased healthy care costs, estimated at $10-15 billion annually(3).            
 While osteoporosis is not directly a cause of tooth loss, most patients affected with 
osteoporosis are elderly and may have an increased risk of tooth loss due to prolonged 
exposure to various factors that are associated with tooth loss.  The need for implant therapy 
can increase as patient ages due to increased risk for tooth loss.   These patients can benefit 
immensely from rehabilitation using dental implants.        
 The use of dental implants in patients with osteoporosis is a debatable issue, caused by 
a lack of mineral density, which can affect initial stability.  Dental implant placement can 
also be affected by the increased bone metabolism in favor of resorption, leading to an 
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altered ability for bone formation.  Medications used to treat osteoporosis have been shown 
to cause a decrease in risk of fracture, however, many lead to oral side effects such as 
bisphosphonate related osteonecrosis of the jaw (BRONJ) or more recently known as 
medication related osteonecrosis of the jaw (MRONJ).   There are an abundance of clinical 
studies reporting on the outcomes of implant therapy in patients with osteoporosis, but 
several fail to differentiate between the effects of osteoporosis and its therapy.  Many studies 
have demonstrated successful osseointegration of dental implants in osteoporotic patients 
with no contraindication for implant therapy(4-6).  However, there are other studies which 
show that osseointegration of implants in patients with osteoporosis could be negatively 
affected(7, 8).     
Section 1.1 Bone Tissue: Gross Structure, Formation 
 Bone is a mineralized and dynamic type of connective tissue that has many functions, 
including: movement, protection, support, hematopoiesis and mineral reservoir(9).  This 
histologically unique tissue is comprised of a complex structure of both organic content and 
inorganic components(9).  The organic components are comprised mainly of type I collagen 
and various other non-collagenous matrix proteins(9).  Despite their location in the body, all 
bones have similar basic structure.  The variability in the overall size and shape of individual 
bones begins during embryonic development and continues up to the pre-adult stage in 
growth(9).  
 The overall organizational structure of bone includes internal and external components 
that all interact with one another to form a delicate equilibrium.  The external structure of 
bone includes an outer layer of dense fibrous connective tissue membrane known as the 
periosteum(9).  This membrane is comprised of two layers, an inner and outer layer, both of 
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which are involved in the functionality of this tissue.  The outer layer is known as the fibrous 
periosteum and it is not in contact with the bone and acts as the location for muscle and 
tendon attachment, along with aiding in nutritional support(9). Cells within the fibrous layer 
are very densely packed together; lymphatics, vasculature neural tissue are also located in the 
fibrous layer(9).  The inner layer, known as the osteogenic periosteum, is the layer adjacent 
to the cortical bone surface(9).  The inner periosteum functions to maintain the osteogenic 
potential of the bone during injury or growth. The internal structural elements include a 
dense outer layer of compact bone which encapsulates the inner supporting network of 
trabecular bone(9).  The porous structure of the trabeculated bone is filled with marrow, 
which is the vital tissue involved in hematopoiesis(9).  A poorly demarcated layer of loose 
connective tissue, known as the endosteum, lines the internal aspect of each bone(9).  The 
role of the endosteum is a physical barrier between the two bone layers; it also acts as a 
source of osteogenic cells(9).  The combination of all of these aspects makes up the 
organizational components of bone. 
 Different cells that comprise the bone have different functions and in health work in 
congruence with one another to maintain form and function, however these same cells can 
function in disease when the balance is tipped.  Histologically, both compact and trabecular 
bones are identical and consist of microscopically unique lamellar types, each of which are 
found in distinct locations with the bone structure.   The osteon is the basic organizational 
unit that consists of concentric lamellae, which form a cylinder of bone surrounding a central 
vascular channel(9).  Osteoblasts are of mesenchymal origin and are mononucleated cells 
that produce the organic matrix that comprises the bone(9).  Osteoblasts not only form the 
structural matrix proteins, but also secrete a multitude of cytokines and growth factors, which 
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regulate cellular function and bone metabolism(9). Osteocytes are osteoblasts cells that have 
become entombed in the mineral matrix they secrete while forming the structure.   These 
cells are located in lacunae and communicate with one another and other cellular types via 
enclosed channels.  These channels are known as canaliculi and allow for the osteocytes to 
sense the biochemical and mechanical environmental changes within the bone and transmit 
signals to induce a response(9).  Osteoclasts are larger multinucleated bone cells responsible 
for the bone degradation, a critical function in maintenance, repair and remodeling 
processes(9).  Osteoclasts originate from monocytes/macrophage lineages and differentiate 
into functional cells when exposed to receptor activator of nuclear factor kappa-B ligand 
(RANKL), macrophage colony-stimulating factor (M-CSF), and tumor necrosis factor alpha 
(TNF-α)(10). 
Section 1.2: Bone Metabolism 
 Because bone is a metabolically active tissue, it is in a constant state of flux in response 
to specific functional and nutritional demands(9).  During childhood, bone turnover is much 
greater than adults, as one ages the rate of turnover rate decreases, yet remains balanced 
during a state of health.  Bone turnover rates for trabecular bone are 15% per year, while 
cortical bone is approximately 5% per year(9).   The cyclical nature of remodeling consists of 
three consecutive phases: resorption, reversal and formation(11).   The resorptive phase is 
initiated with the migration of partially differentiated mononuclear pre-osteoclast and lasts 
approximately 2 weeks(11).   The main player in the resorptive phase is the osteoclast, which 
dissolves the bone mineral, and enzymatically degrades extracellular matrix (ECM) 
proteins(10).  The initiation of the resorptive phase is systemically controlled via four main 
hormones: vitamin D3 (1,25 Vit D3), parathyroid hormone (PTH), calcinontin, and 
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estrogen(12).  Calcitonin, PTH and 1,25 Vit D3 are all secreted with the intention to control 
the levels of serum calcium to maintain a precise physiological range(12). With the 
completion of the resorptive phase, mononuclear cells will appear on the surface of the bone 
and prepare the surface for bone formation by osteoblasts(11).  These reversal mononuclear 
cells provide signals for the differentiation and migration of osteoblasts and can last up to 4 
to 5 weeks(11).  Specific factors are created by the differentiated osteoclasts and 
mononuclear reversal cells, or released from the demineralized matrix trigger the initiation of 
the formation phase(9).  The formative phase main cellular constituent is the osteoblast, 
which produces the organic bone matrix and aids in mineralization(13). As osteoblasts form 
bone and mature, they produce more OPG and less RANKL, resulting in the inhibitory action 
of osteoclasts(9).  The formation phase can continue for up to 4 months(11).  Mechanical 
force also plays a role in bone remodeling and architecture through local and systemic 
responses(14). The osteocyte, which a post-mitotic osteoblasts-derived cell, acts as a 
mechanosensor and an endocrine cell, facilitating the signal transduction in reaction to 
mechanical or metabolic stimuli(15). 
Section 1.3: Bone Metabolic biological pathways and gene expression  
 The interplay of osteoblastic and osteoclastic function forms a delicate balance created 
by a multitude of unique and different cytokines, growth factors, and hormones(9).  In 
disease states, however, the balance is tipped leading to pathologic bone formation or loss.  
Although the transcriptional regulation and signaling pathways are not well understood, the 
formation bone requires highly controlled biologic pathways stemming from the up-
regulation or down-regulation of key genes involved in the differentiation and maturation of 
osteoblastic cells(16).  Different transcription factors are involved in the differentiation 
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process from mesenchymal stem cells or hematopoietic precursor cell into their respective 
bone cells(9).  Only select transcription factors will be discussed in this review.  Osteoblastic 
phenotyptic commitment is regulated by principal transcription factors, one of which is 
transforming growth factor/ bone morphogenetic protein (TGF/BMP) and fibroblast growth 
factors (FGF)(17).  The transcription factors RunX2 and Osterix are essential for control of 
commitment and differentiation of mesenchymal stem cells (MSCs) into osteoblasts(9).   The 
threshold of RunX2/Osterix will determine the pathway of commitment to either osteocyte or 
chondrocyte cell lineage(17).  Several hormones and cytokines are involved in a dosage and 
time dependent fashion, influencing the progression of MSCs to an osteoblastic lineage either 
directly or indirectly(18).  Receptor-activated nuclear factor (RANK) and its ligand 
(RANKL), expressed on the plasma membrane of osteoblast progenitor cells(9). RANKL 
then binds to the RANK expressed on plasma membrane of osteoclast progenitor cells, 
inducing the differentiation of osteoclasts(9).  The osteoclasts also secrete a decoy to 
RANKL, known as osteoprotegrin (OPG), which blocks the binding of RANK and RANKL, 
creating a type of self-regulatory function(9). Localized control of the remodeling ensures 
that bone is removed when damaged and replaced where needed(19).  Fibroblast growth 
factors (FGF) are growth factors that are involved in the regulation of cellular proliferation, 
differentiation, survival, and migration of osteoblasts(20).  An osteocytic marker, phosphate-
regulating gene with homolog X chromosome (PHEX), is one of the many “mineralization-
related genes” which are involved in the regulation of mineralization and phosphate 
metabolism(21).  The genes discussed in this section and their ontology classification is 
shown in Table 1.1.   
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Gene Name Gene Ontology Classification 
ALPL Skeletal system development, biomineral 
tissue development 
BGLAP Regulates bone remodeling and energy 
metabolism 
BMP4 Osteoblast differentiation, positive regulation 
of pathway-restricted SMAD protein 
phosphorylation, positive regulation of bone 
mineralization 
TGFB3 SMAD protein import into nucleus, cell 
proliferation 
FGFR2 Influences mitogenesis and differentiation 
VCAM1 Mediates leukocyte-endothelial adhesion and 
signal transduction 
EGFR Binds to epidermal growth factors, induces 
cell proliferation 
VDR Involved in mineral metabolism 
PHEX Involved in bone mineralization and renal 
phosphate reabsorption 
VEGF-B Regulates the formation of blood vessels 
ITGA1 & ITGA2 Involved in cell-cell adhesion 
COL Skeletal development 
CTSK Proteolysis, bone resorption 
SERPINH Plays a role in collagen biosynthesis, 
endochondral ossification 
FN1 Extracellular matrix structural constituent, 
angiogenesis, cell adhesions, cell migration, 
regulation in cell shape 
	
Table	1.1:	Molecular	assessment	of	osseointegration.	Adapted	from	Thalji	&	Cooper	2013(22). 
While the mechanisms involved in the local control and systemic control of bone remodeling 
is not completely understood, the current known major mechanisms have been reviewed in 
the most basic sense.  
Section 1.4 Osteoporosis: Definition, types and pathophysiology 
 The National Institute of Health (NIH) defined osteoporosis as a “skeletal disorder 
characterized by compromised bone strength predisposing a person to an increased fracture 
risk”(3).  It has been described by some as a multifactorial age related bone disease that is 
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characterized by low mineral density, microarchitecture deterioration along with changes in 
the mineral property of the bone causing enhanced fragility, ultimately leading to a higher 
susceptibility for fracture(23).  Bone strength, density and quality are all utilized as 
measurements to evaluate the effect of bone metabolic diseases, specifically osteoporosis; all 
are interdependent on one another.   Bone strength is the echoes of the integration of bone 
density and quality, while bone density is simply expressed in units: grams per area or 
volume(3).  Bone quality is the architecture, mineralization, damage accumulation, and 
turnover (3).  There are two types of osteoporosis, primary and secondary.  Primary 
osteoporosis most often occurs after the onset of menopause, however, it can occur in both 
sexes and generally is seen later in life for males(3).   Secondary osteoporosis is due to the 
effects of specific medications such as glucocorticoids, diseases or disorders causing 
malabsorption(3).  Primary osteoporosis mainly affects the trabecular bone, while secondary 
osteoporosis is characterized by the loss of cortical and trabecular bone(24).   The micro-
architectural differences can be seen upon gross histologic evaluation and with more detail 
utilizing scanning electron microscopy (SEM).  
 The pathophysiology of osteoporosis is multifactorial, but stems from the inability of 
the formative bone phase to outpace the resorptive bone phase, leading to an overall loss of 
mineral and detrimental changes in microstructure. In health, targeted remodeling is 
completed in order to repair sites of micro-damage, while stochastic remodeling is completed 
to maintain plasma homeostasis(25).  If stochastic remodeling is excessive it can lead to 
skeletal weakness through loss of bone mass(25).  While remodeling favors the resorptive 
phase, trabeculae become thinner and fewer in number as well as lose their connectivity(26).  
Skeletal mass and density will then have been affected to the point of structural instability, 
	 9	
leading to increased risk for fracture(27). An assessment of the remodeling rates can be done 
with the use of markers of bone resorption: N-terminal telopeptide (NTX) or C-telopeptides 
of type I collagen (CTX), and markers of bone formation: OC, procollagen type I N-terminal 
propeptide (PINP) and bone-specific alkaline phosphatase (BSAP); can be used to evaluate 
increased fracture risk, however, these are difficult apply clinically in patients(25).  
Section 1.5: Diagnosis, Prevalence and Burden 
 The changes in bone mineral density (BMD) microarchitecture that lead to fractures 
drastically impact the quality of life and can lead to temporary or permanent disability(28). 
Therefore, the diagnosis of osteoporosis is extremely important in the clinical setting to 
prevent fractures and decrease fracture risk.  In a clinical setting, the utilization of patient 
history and physical exam coupled with diagnostic tests are key to an accurate diagnosis and 
evaluation for intervention.  In many cases, the disease can be undiagnosed until the patient 
has suffered from a fracture.   The diagnosis of osteoporosis is given when the BMD exceeds 
more than 2.5 standard deviations (SD) below the normal mean for a young adult woman(3).  
BMD is reported using T-scores, and a routine and noninvasive method for the measurement 
of BMD is done by dual energy X-ray absorptiometry (DXA), it is also considered the gold 
standard for BMD assessment(29).   A BMD T-score between 1.0 and 2.5 SDs below the 
young adult woman mean equates to a diagnosis of osteopenia, while a BMD T-score equal 
to or above -1.0 is reflects as a normal score(30).  A test for BMD will also produce a Z-
score that allows for the comparison of the patient’s BMD to that of a healthy age matched 
individual. Both gender and ethnicity/race play a role in the prevalence and fracture 
incidence(3).  The ranges for both T-scores and Z-scores can be seen in Table 1.2.    
 
	 10	
BMD Scoring Category 
Z-score ≤ 2.0  Below expected range for age 
and sex match 
Z-score > 2.0 Within expected range for age 
and sex match 
T-score ≤ 2.5 below normal Osteoporosis 
T-score 1.0 to 2.5 below normal Osteopenia 
T-score ≥ 1.0 below normal  Normal/Healthy 	
Table	1.2:	BMD	Diagnostic	Categories.	Adapted	from	Leslie	et	al		2006	(31). 
 
 All ages, races and ethnicities can be affected by osteoporosis, however, the majority 
are post-menopausal white women(3).  Although both men and women show an age-related 
decline in BMD towards the beginning of midlife, women have a much more pronounced 
BMD loss after the onset of menopause, which occurs roughly around the age of 51 for most 
women(3).   Menopause is defined as the reduced secretion of estrogen and progesterone, 
leading to the cessation of menstruation(32).  It is diagnosed 12 months after amenorrhea not 
resulting from a pathological cause, but can be the result of surgical intervention, 
chemotherapy or radiation(32).  With the depletion of estrogen, the inhibition of osteoclasts 
is lost, along with decreased intestinal calcium absorption caused by the flux of calcium into 
the plasma from bone resorption resulting in the reduction in parathyroid hormone levels(33).  
The damaging effects of osteoporosis on BMD can be seen 5 to 7 years surrounding the onset 
of menopause, whereby women lose approximately 12% of their total bone which is the 
equivalent to 1 T-score measured by DXA.  To help combat modifying factors and increase 
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the effectiveness of the fracture risk assessment, WHO developed the Fracture Risk 
Assessment Tool (FRAX)(34).  FRAX utilizes risk factors that were identified from several 
meta-analyses; its algorithms estimate a 10-year probability of fracture(34).  Risk factors for 
fracture include age (40-90 years), weight, height, sex, low femoral neck BMD, history of 
previous fracture, parental history of hip fracture, current tobacco habits, use of 
glucocorticoids, rheumatoid arthritis, alcohol intake and other causes attributed to secondary 
osteoporosis(35).  FRAX will then provide a numerical value which is the ten year 
probability of a major osteoporotic fracture as a percentage and the decision for intervention 
can be determined from the management chart seen in Figure 1.1(35).  With osteoporosis 
related fractures comes numerous medical related expenses, estimated at 15 to 20 billion 
dollars yearly in the US which, much of the cost is paid by Medicaid and Medicare(36).  
Osteoporosis related fractures account for more combined deaths and morbidity than any 
single type of cancer, with the exception of lung cancer(37).  The global burden of 
osteoporosis is normally quantified by disability adjusted life years (DALYs), which factors 
the years of life lost due to fracture and the disability of those who survive(38).   It was 
calculated that in 2000, an estimated 9 million osteoporosis related fractures accounted for a 
total of 5.8 million DALYs(37).  This number encompasses 0.83% of the world-wide burden 
for non-communicable disease(37).  
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Figure	1.1:	Management	Chart	for	Osteoporosis.		Dotted	line	shows	the	intervention	threshold.		Reproduced	
with	permission.(39). 
 
Section 1.6: Treatment of Osteoporosis 
 Osteoporosis is treated in a varying number of ways, including changes in lifestyle 
approaches and pharmacological interventions.  Lifestyle changes range from smoking 
cessation, weight bearing exercises, calcium and vitamin D supplementation.  However, if 
the patient falls into an increased risk category based on their T/Z-scores or other risk 
assessment tool, pharmacologic intervention is necessary.  Prior to pharmacologic 
intervention, the cost, risk of adverse effects versus benefit, and limitation of the medication 
should all be considered(40).  The main objective of each pharmacologic treatment modality 
is to increase bone mass and prevent further loss.  The following medication categories have 
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been utilized in the treatment of osteoporosis: antiresorptive agents and bone-forming agents.  
Antiresorptive agents include Hormone Replacement Therapy (HRT), bisphosphonates, 
calcitonin, parathyroid hormone (PTH), RANKL inhibitor, and selective estrogen receptor 
modulators (SERMs)(41). The current bone-forming agent available on the market is 
teriparatide.  Both antiresorptive and bone-forming agents have a range of dosing frequencies 
and routes of administration that are tailored specifically for each medication(41).  With the 
use of pharmacologic intervention, vertebral fracture risk is reduced by 30-70%, dependent 
on the agent and level of adherence(41).  The decision to prescribe a pharmacologic 
intervention or utilize life style changes or dietary supplementation needs to be completed 
after careful evaluation of the individuals’ current BMD score and relative risk. 
 Bisphosphonates historically have been one of the most frequently used osteoporotic 
treatment medications.  The chemical structure of bisphosphonate is similar to inorganic 
pyrophosphate (PPi), allowing this type of drug to perform partially as a nonhydrolyzable PPi 
analog(42).  The chemical structure of several bisphosphonates and PPi can be seen in Figure 
1.2 below. 
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Figure	1.2:	Chemical	Structure	of	Bisphosphonates	and	Inorganic	Pyrophosphate.		Reproduced	with	
permission.	(43).	 
 In general, bisphosphonates are very hydrophilic with poor lipophilicity relating to poor 
oral bioavailability with only <1% is absorbed from the gastrointestinal tract after oral 
administration(44).  To offset the poor absorption, increased doses can be given as 
bisphosphonates have a dose-dependent absorption(44).  The overall mechanism of 
bisphosphonates includes the localization of the drug to the bone where they bind to the 
calcium in hydroxyapatite due to their high affinity for bone, as they are synthetic analogues 
to PPi(45).  The chemical structure of bisphosphonates greatly affects their function; the 
hydroxyl groups are critical for the binding to calcium and the terminal functional group 
bound to the central carbon determines the resorption inhibition potency(45).   It has also 
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been shown that bisphosphonates can prevent apoptosis of osteocytes and osteoblasts via the 
rapid activation through phosphorylation of extracellular signal regulated kinase (ERK) 
pathway(46).  As remodeling occurs, the drug is incorporated into osteoclast, causing 
reduced resorptive activity and eventually cell death(47).  The ability to be preferentially 
incorporated into the bone and obtain skeletal retention is based on the availability of 
hydroxyapatite binding sites(45).  The hydroxyapatite binding sites are more readily 
available in bone metabolic disorders that favor resorption(45).  Any drug that is not 
incorporated into the skeleton is then rapidly cleared from circulation by renal excretion(45).   
 There are two types of bisphosphonate types, nitrogenous and non-nitrogenous.  The 
first generation bisphosphonates are non-nitrougenous and include: etidronate, clodronate 
and tiludronate(45).  These non-nitrogen containing bisphosphonates become incorporated 
into newly formed adenosine triphosphate (ATP) molecules which accumulate inside 
osteoclasts and are cytotoxic due to their inability to by hydrolyzed, leading ultimately to 
cellular apoptosis(45).  Second and third generation are nitrogen-containing and include: 
alendronate, risedronate, ibandronate, pamidronate and zoledronic acid(45).  These later 
generation bisphosphonates bind and inhibit a key regulatory enzyme critical to the 
production of cholesterols, isoprenoid lipids and other sterols(45).  This inhibition leads to 
interference in key cellular function in osteoclasts, leading to apoptosis(45).  The mechanism 
of the different types of bisphosphonates can be seen in Figure 1.3, below.  
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Figure	1.3:	The	cellular	and	biochemical	mechanisms	of	action	of	bisphosphonates.		Reproduced	with	
permission.	(43). 
 The route of administration of bisphosphonates is important for dosage, onset and risk 
for potential side effects. The maximum effects of resorption suppression can be seen around 
3 months after the initiation of the oral bisphosphonate(45).  The rate of bone remodeling 
dictates the half-life and due to the length of natural bone turnover the half-life can be at least 
10 years(44).  These long half-lives are the reason that a drug holiday would not allow for the 
recovery of osteoclastic function and return of normal bone turnover(45).   The effect of 
binding affinity of different bisphosphonates and the relative uptake and detachment from the 
osseous surface can be visualized in Figure 1.4. 
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Figure	1.4: Effect	of	Binding	Affinity	of	Bisphosphonates	on	their	Uptake	and	Detachment	from	bone	surfaces	
and	their	re-cycling.		Reproduced	with	permission.	(43).	
	 
Bisphosphonates have been associated with various adverse side effects and safety concerns.  
Some of the adverse side effects are based on the mode of administration; oral administration 
has been associated with gastrointestinal effects(45).  However, acute phase reactions 
including fever, myalgia, arthralgia and headache are more common with intravenous (IV) 
administration of bisphosphonates(45).  One of the most significant adverse events with 
severe oral implications is osteonecrosis of the jaw (ONJ), which is thought to be caused by 
an over suppression of bone turnover(48).  This over-suppression allows for the persistence 
of micro-damage and micro-fractures that accumulate over time(49). Even with the limited 
osteoclastic activity, osteoblastic activity is still affected, resulting in bone formation that is 
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rigid and brittle, with an osteoporotic architecture(50).  The majority (94%) of reported cases 
have been in patients with intra-venous (IV) second and third generation bisphosphonate 
therapy for the treatment for metastatic bone diseases(48).  Of the areas in the mouth that are 
affected, there is a higher propensity for the mandible to be affected (2:1 ratio) as compared 
to the maxilla(48).   More than half of the patients affected (60%) reported a dento-alveolar 
surgical procedure prior to onset, however, spontaneous onset without injury or surgical 
intervention can occur(51).   The fragility of the mucosal barrier against trauma and increase 
exposure to oral pathogens are reasons for increase susceptibility for osteonecrosis of the oral 
cavity(45).  The most important risk factors for BRONJ are the total dose, history of trauma, 
dental surgery or dental infection.     
 The most abundant mineral in bone is calcium; bone acts as a reservoir for the storage 
of over 98% of the body’s total calcium(52).  The majority of peak bone mass is genetically 
determined and acts as a significant risk determinant for future fracture risk(52). The main 
advantageous effects of calcium supplementation in the increase of BMD and reduction in 
fracture risk is most pronounced in the later postmenopausal years, while there is less of an 
effect in the early post menopausal years(52).  Research has shown that calcium supplements 
alone improve BMD but are unsuccessful in their ability to reduce the risk for fracture(53).   
Unfortunately, the use of calcium supplementation is not without risk as evidence shows 
calcium supplementation has an increased risk of cardiovascular events such as myocardial 
infarction (MI)(53).  
 Many practitioners have extensively used vitamin D and calcium supplementation as an 
intervention for at-risk patients; however, many overlook this need prior to or during 
bisphosphonate therapy.  Hypovitaminosis D is more common in patients taking 
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bisphosphonates, due to limited dietary absorption and reduced intake, possible renal 
impairment and higher incidence for limited sun exposure(45).  Although currently there is 
no consensus on the optimal 1,25 Vit D3, however 30ng/mL, and reduced vitamin D serum 
levels cause a reduction in calcium absorption (10-15%) and phosphorus absorption (60%) 
(54). Hypovitaminosis D can also lead to skeletal muscle weakness which can increase the 
risk for falls, increasing the risk for fractures(54).  With the drop in intestinal calcium 
absorption there is an increase production in parathyroid hormone increasing the skeletal 
leaching of calcium to supplement low serum levels(54).  The metabolism of vitamin D in 
the regulation of calcium, phosphorous and bone metabolism can be seen in Figure 1.8. 
 An endogenous polypeptide hormone used in the treatment of postmenopausal 
osteoporosis through its affect on osteoclasts is calcitonin (CT)(55).  With specific receptors 
on osteoclasts, the binding of calcitonin causes the movement out of the resorptive pit with 
the loss of the brush border; it also modifies the internal structure of osteoclasts by inhibiting 
multiple cytoplasmic functions key to bone resorption(56).  Calcitonin shortens the lifespan 
of number of osteoclasts, it also blocks the union of mononuclear marrow progenitor cells 
that become osteoclasts, thereby reducing the number of osteoclasts(57).  More recently 
research has shown that calcitonin aid in increasing the survival rate of osteoblasts and 
osteocytes(46).  Early calcitonin was administered via injection, leading to issues in 
compliance and the need for the creation of suppository and nasal spray modes of 
administration(58).  The effectiveness of calcitonin on osteoporosis treatment has shown a 
30% reduction in hip fractures(59).  It has also been suggested that calcitonin may have an 
analgesic effect on patients with acute vertebral fractures, removed from its effect on 
osteoclasts(60).  It has been suggested an osteoclastic resistance to prolong administered 
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calcitonin can occur and that intermittent administration may help to avoid tolerance(61).  
Unlike bisphosphonates, the effects of calcitonin on osteoclasts is reversible and the 
medication does not persist in the bone even after longlapses in medication 
administration(62).	
 Teraparatide (TPTD) or recombinant parathyroid hormone is an anabolic therapy was 
the first FDA approved medication for the treatment of osteoporosis that stimulates bone 
formation rather than BMD reduction(63).  TPTD is recommended for the treatment of 
osteoporotic female patients with a high fracture risk and male patients at high fracture risk 
due to primary or hypogonadal osteoporosis.  Parathyroid hormone in the body controls 
calcium serum levels through bone resorption or bone formation, with a sustained exposure 
results in net bone loss, while bone gain is due to intermittent exposure(63).  Teraparatide 
(TPTD) is a modified parathyroid hormone that works by directly stimulating bone formation 
and increases the initiation of novel remodeling sites(64).  TPTD has several additional 
effects on bone.  TPTD stimulates the proliferation of cells in the osteoblastic lineage 
through the activation of calcium protein kinase(65).  Through increased expression in the 
Wnt signaling, there is an increase in bone formation and reduces apoptosis of 
osteoblasts(66).  It has been shown to can increase the amount of tracbecular bone and 
cortical thickness with superior trabecular microarchitecture.  Due to some of the concerns 
with the formation of osteosarcoma formation, TPTD is recommended for a maximum 
duration of 24 months to limit the risk(64).  Additionally, nausea, leg cramps and dizziness 
are the most commonly reported side effects with TPTD administration. TPTD has also been 
linked to life threatening hypercalcemia which leads to a multitude of symptoms including 
arrhythmias, coma and renal dysfunction(67).  The influence of PTH on bone metabolism 
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can be seen in figure 1.5 below. f  
 
Figure	1.5:		Effects	of	parathyroid	hormone.	Reproduced	with	permission(63).	 
 Denosumab is a unique pharmacological intervention that is a fully human 
immunoglobulin (Ig) G2 monoclonal antibody for RANKL, leading to the inhibition of 
osteoclastic activity, and increases BMD(68).  Denosumab has a high affinity and specificity 
to RANKL, mimicking endogenous osteoprotegrin (OPG)(69).  It is administered via 
subcutaneous injection once every 6 months(70). The mechanism of Denosumab is that it 
binds RANKL, blocking its activity with osteoclastic RANK receptors(68).   The interaction 
of RANK with RANKL is key for the development, function and survival of osteoclasts(71).  
Denosumab has been shown to be as effective as the most efficacious bisphosphonate and 
has been shown to further reduce the rate of bone metabolism even in patients previously 
taking bisphosphonates(70).  Adverse effects include symptomatic hypocalcemia if not 
corrected prior to treatment and risk of ONJ, more recently categorized as medication related 
osteonecrosis of the jaw (MRONJ)(69).            
 Hormone Replacement Therapy has been utilized in the treatment of osteoporosis due 
to its ability to significantly reduce fractures, however, several serious adverse reactions have 
	 22	
limited its use(72).  Hormone replacement consists of either estrogen as a single medication 
or as estrogen and progesterone combined.  Originally, HRT was prescribed to combat the 
associated symptoms and was thought to have added cardiovascular benefits(73).  With the 
use of HRT, its affect on BMD and fracture reduction was seen to be valuable in the 
treatment of post-menopausal osteoporosis.  The use of HRT waned after the severe side 
effects, including increased risk for breast cancer and cardiovascular events(74).                    
 Selective estrogen receptor modulators (SERMs) were developed for the treatment of 
breast cancer, however today; this class of drug is used for the treatment of breast cancer, 
osteoporosis and other postmenopausal symptoms.  SERMs are tissue selective estrogen 
agonists for bone, however, it can act as antagonists to estrogen depending on the type(75).  
In the treatment of osteoporosis, SERMs work on estrogen receptors, down-regulating the 
activity of osteoclasts and ultimately lessening bone resorption(75).   Multiple clinical trials 
concluded that SERMs aid in the maintenance of BMD, however, the fracture reduction risk 
is anatomically limited(75).  Unlike BPs, SERMs have not been shown to have a continued 
effect on bones and once SERM administration is suspended the effects on BMD can no 
longer be seen(75).  Side effects include menopausal-like symptoms such as hot flashes as 
well as venous thromboembolic events (VTEs) and cardiovascular events, as well as an 
increased risk of endometrial cancer(76).       
 Several drug types are utilized in the armamentarium for the treatment of osteoporosis, 
each with a unique mechanism of action.  However, the clinical benefit versus the risk must 
be weighed prior to administration of the drug or combination of drugs.  Due to the rapid 
bone turnover in the jaws, many of these mediations may have more pronounced effects in 
the oral cavity.  Because some drugs can have oral manifestations and may affect the 
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outcome of implant therapy, precaution should be taken to inform the patient of potential 
risks.  An overview of the mechanism and safety concerns can be seen in Table 1.3 below.  
Medication Mechanism Safety Concerns 
Bisphosphonates Binds to hydroxyapatite, induces 
osteoclast apoptosis, can decrease 
osteoblast apoptosis 
BRONJ(48),  esophageal cancer 
(77) 
Selective estrogen 
receptor modulators 
(SERMs) 
Agonist for the estrogen receptor in 
bone 
Venous thromboembolic 
events(76) 
Hormone 
Replacement 
Therapy 
Prevents osseous changes triggered 
by estrogen withdrawal 
Coronary Heart diseaese(74), 
Breast cancer, VTE (78) 
Calcitonin Reversibly binds to osteoclasts and 
inhibits bone resorption  
Cancer (79) 
Teriparatide Binds to osteoblasts and stimulates 
osteoblast activity more than 
osteoclast activity 
Osteosarcoma(64) 
Leg cramps, hypercalcemia 
Denosumab Prevents interaction of RANK with 
RANKL. Reduces osteoclast 
differentiation, survival and activity 
MRONJ (69) 
Calcium 
 
Vitamin D 
supplementation 
Provides calcium for bone 
remodeling, maintains blood calcium 
 
Aids in calcium, phosphorous 
regulation 
Kidney stones (80), cardiovascular 
events (81) 
 
Chronic toxicicty at 
50,000IU/day(82) 
Table 1.3: Osteoporosis therapies, mechanism of action and safety concerns. 
 
Section 1.7: Dental Implants and Osseointegration 
 Dental implants are a popular replacement in the event of tooth loss or congenitally 
missing teeth.  Placement and restoring dental implants have become more predictable as 
implant design and surfaces have evolved, however, even with these advances, between 3-
10% of implant failures still occur(7, 8). Implants are embedded surgically in the jaw and are 
fixed initially in bone due to a friction fit known as primary stability, and after remodeling, 
secondary stability occurs.  Osseointegration is defined as the “direct structural and 
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functional connection between ordered living bone and the surface of the load-covering 
implant”(83).  Later it was described as a healing process dependent on time, whereby a rigid 
fixation of a bio inert material is clinically asymptomatic and can maintain a functional 
load(84).  Implant fixation is of critical importance to obtaining sufficient osseointegration of 
a dental implant and help prevent failure in stability(85).  When an implant is placed, there is 
injury to the bone and remodeling must occur in order for the implant to survive.  
Characteristically around implants, de novo bone formation occurs by way of the 
intramembranous pathways as opposed to an endochondral pathway(86).  Osteogenesis 
around an implant is analogous to osteogenesis during fracture repair; initial formation and 
stabilization of a clot, followed by inflammatory phase, then proliferative/reparative phase, 
and finally a remodeling phase(87).  In the initial formation and stabilization of a clot, local 
plasma proteins from the blood are adsorbed on the surface of the implant, setting into 
motion the clotting cascade(88).  The initiation of the clotting cascade allows for the 
activation of platelets and the release of various cytokines, which are important in 
angiogenesis, collagen synthesis, and bone turnover(88).   The migration and aggregation of 
neutrophils to the osteotomy herald the start of the inflammatory phase at around 3-4 days 
post implant surgery(88).   Neutrophils are then slowly replaced by macrophages which 
occurs around 5-6 days post implant surgery(88).   The proliferative phase is marked by 
angiogenesis which allows for the localization of nutrients and cytokines to induce 
mesenchymal cells to differentiate into fibroblasts and osteoblasts, to form an immature 
connective tissue matrix(89).  Over time, the matrix becomes more mature and more 
organized.  Remodeling is the coupling of the resorption and deposition of bone through 
osteoclastic and osteoblastic activity respectively(87).    It is important to note that 
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osteogenesis occurs in two locations after dental implant placement; on the surface of the old 
bone, known as distance osteogeneisis; and on the surface of the implant, known as contact 
osteogenesis(87).   
 Initial mechanical stability is another vitally important aspect for proper 
osseointegration, as micromotions of 150µm or more lead to fibrous encapsulation of the 
dental implant(90).  A fibrous encapsulation prevents intimate contact of bone onto the 
implant surface, creating a complete lack of osseointegration, leading to failure.  The 
formation of peri-implant bone is normally assessed utilizing multiple parameters including 
volume, architecture, and bone to implant contact as a fraction of the total implant surface.  
Originally, the gold standard for the evaluation of osseointegration was microscopic or 
histologic analysis, however this cannot be completed outside of clinical research(91).  
Currently, the use of radiographic comparison, cutting torque resistance, reverse torque, 
modal analysis and resonance frequency analysis have all been proposed as new 
methodologies for the evaluation of implant osseointegration(91).  Any systemic condition, 
factor or medication that affects any phase of osseointegration can, by default, affect the 
success of osseointegration and impair implant success and/or survival.  On the other hand, 
implant failure is defined as the first occurrence for which the quantitative performance of a 
specified implant falls below a specified acceptable limit(92).   
Section 1.8: Outcomes and Factors Affecting Dental Implants 
 Systemic conditions such as diabetes mellitus, osteoporosis and cardiovascular disease 
can affect implant success and/or survival by increasing the patient’s susceptibility to other 
disease or by causing a malfunction in the healing process(93).  Although there are a handful 
of systemic factors that have been linked to the increased failure of dental implants, there is 
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no one systemic condition that is an absolute contraindication for dental implant therapy(8).  
With this being said, the overall success rate of dental implants is quite high, ranging 
upwards to 98%, while cumulative survival rates were 94.6% after a follow up of over 13 
years(94).   The definition of success and survival for implants differs slightly and depends 
specifically on the criteria of the article in question.  In general, implant success criteria has 
not changed much and remains that a single unattached implant remain immobile when 
tested, lack of radiographic peri-implant radiolucency, vertical bone loss less than 0.2mm 
after the first year of loading, absence of pain or irreversible signs and symptoms(95).  While 
implant survival is defined as the physical retention of the implant in the patient’s mouth, 
lacking physical removal from the oral cavity(96).  Therefore, implant success requires 
certain criteria be met that involve function, patient satisfaction and physiology(97).  While 
implant survival does not have to meet all the criteria other than function(98).  
Section 1.9: Implications of Osteoporosis and Dental Implant Therapy 
 Patients diagnosed with osteoporosis undergo a variety of skeletal changes which can 
impact the ability to place implants without prior augmentation procedures due to increased 
alveolar ridge resorption(99).  Reports also indicated that patients with osteoporosis have an 
altered trabecular pattern in posterior aspects of the mandible and anterior aspects of 
maxilla(100).  It has also been shown that osteoporotic patients demonstrate increased 
resorption and thinning of the mandibular inferior cortical margin(101).  In addition, there 
have been anecdotal reports indicating an increased incidence of maxillofacial fractures in 
osteoporotic patients with dental implant therapy(102).  Osteoporosis and various other 
systemic diseases have fallen into the category of relative contraindications, and the clinician 
must evaluate the patient to determine if they are a candidate for implant therapy based on 
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stability of the systemic condition and assessing if medications used to treat the condition 
may interfere with implant outcomes(103).  Osteoporosis is notable in that fact that it is 
subject to controversy for its importance and effects on dental implant outcomes, and has 
been debated if it affects implants outcomes.  The current bone quality classification consists 
on a scale of 1 to 4 based on the amount of cortical and trabecular bone present.  Type 1 bone 
is a homogenous dense cortical bone throughout the entirety of the implant site, while type 2 
bone consists of a thick outer cortical layer surrounding a core of dense trabecular bone(104).  
Type 3 bone consists of a thin layer of compact cortical bone surrounding a core of dense 
trabecular bone, while type 4 bone is made of a thin layer of cortical bone surrounding 
trabecular bone with low density(104).   The differences in bone quality types as well as the 
different jaw shapes related to factors affecting implant placement can be seen in figure 1.6. 
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Figure	1.6:		Classification	of	bone	quality	and	jaw	shape.	Reproduced	with	permission.	(105). 
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 Several longitudinal studies on implant failure rates reports increased failure risk for 
implants placed in type 4 bone locations(106, 107).   Increased failures in type 4 bone are 
important because patients affected with osteoporosis classically have type 4 bone due to loss 
of bone mineral density(108).  With controversy in the literature, histologic studies 
demonstrated no difference in bone to implant contact (BIC) among healthy and osteoporotic 
patients (109).  However, a large retrospective study concluded that osteoporosis was a 
significant variable for early implant failure(7).    
 Currently, the role of anti-resorptive medications is still unclear on their effects of 
implant outcomes(7).  The first reports of osteonecrosis of the jaw due to anti-resorptive 
medications, (109, 110) specifically bisphosphonates, was in 2003(111).  Monoclonal 
antibodies gained popularity to aid in treating osteoporosis and other skeletal metabolic 
and/or metastases as they were thought to have fewer side effects, however, the first report of 
ONJ related to these types of medications was reported in 2010(112).  Due to the increased 
number of cases, and their effect on bone metabolism, there has been an increase in the 
number of publications on bisphosphonates and other anti-resorptive drugs related to 
osteonecrosis of the jaw(113, 114).  Bisphosphonates are medications used to treat a variety 
of skeletal disorders, ranging from metabolic bone conditions to metastatic bone diseases, 
resulting in the maintenance of bone density and maintenance in serum calcium levels(62, 
115).  The prevalence of ONJ varies depending upon route of administration, condition being 
treated, length of use, and population, ranging from <1% to as high as 28%(116, 117). 
Because ONJ appears to be localized to the oral cavity, surgical dental interventions may put 
patients at an increased risk for the development of ONJ, including extractions and possibly 
dental implants during or prior to the initiation of anti-resorptive therapy(117).  Currently, 
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there is little solid epidemiological evidence supporting compromised outcomes of implant 
therapy in patients treated with anti-resorptive medications.  Compromised outcomes in 
dental implant therapy due to anti-resorptive mediations can have an extensive impact as 
millions of patients, as both men and women with osteoporosis or other metabolic bone 
disorder are taking these medications. 
 Overall opinion in the field is more research is needed to ascertain if a true correlation 
exists between alveolar changes in the maxillofacial region and overall skeletal bone 
mass(118).   Also, additional research will be able to evaluate if medications used to treat 
osteoporosis have effects on implant outcomes.       
Section 1.10: Porous Tantalum Trabecular Metal: Production and Biologic Influence 
 Porous tantalum trabecular metal (PTTM) is made up of a rare transitional metal, 
Tantalum (Ta), and is known for its resistance to corrosion.   It is a member of the refractory 
metal groups, allowing it to be incorporated in various alloys(119).  Anders Gustav 
Ekebereg, a Swedish chemist discovered Ta in 1802(120).  Ta is predominantly mined in 
western Australia and extracted from tantalite, but can be produced as a by product of tin 
mining(121).  Previously, Ta had restricted applications in the medical field due to its rarity 
and the difficulty in manipulating solid Ta(119). Ta is overly reactive to oxygen, however, 
due to this exaggerated reactivity, the formation of oxides on the surface is immediate when 
exposed to oxygen, rendering the surface inert(119).  Its use in the medical field includes 
orthopedic implants, electrodes for pacemakers, and devices for nerve repair(122, 123). Ta 
was incorporated in orthopedic implants to mimic the natural structure of trabecular bone. 
PTTM has a structure similar to trabecular bone through the use of repeating dodecahedron 
three dimensional repeats(124).  The structural morphology is constructed through the use of 
	 31	
thermosetting foam polymer foam, which has undergone pyrolysis, thus creating a vitreous 
carbon scaffold(125).  Tantalum is then deposited on the surface of the scaffold through the 
use of vapor deposition and infiltration(126). Due to the microarchitecture of PTTM it has a 
low modulus of elasticity, which is similar to that of cancellous bone, leading to more ideal 
dispersion of load and a reduced stress shielding phenomenon(124, 127).  
 The porous structure of PTTM has a biologic impact through the induction of rapid 
angiogenesis by adhesion of serum proteins, leading to recruitment of osteoblastic precursor 
cells and subsequent matrix formation(128).  PTTM has a higher degree of porosity than 
traditional titanium implants(124).  Orthopedic surgeons have long utilized porous tantalum 
trabecular metal (PTTM) for its ability to enhance peri-implant wound healing.  The use of 
PTTM in orthopedic implants over the years has shown excellent vascularization, bone 
ingrowth, osteoconductivity and biocompatibility(125, 129). Tantalum has been shown to be 
bioactive by forming a bone-like apatite layer when exposed to body fluid, and biologically 
binds to bone(130, 131).  The porous structure provides a biologically similar scaffold shape 
to trabecular bone and allows for the bone in-growth and mechanical attachment to implant 
surfaces(125, 132).  The bone ingrowth due to the porous structure has lead to the concept 
known as “osseoincorporation”(124, 125).   
Summary   
Throughout the history of implant therapy, the goal has been the formation and 
maintenance of osseointegration, a direct connection between the hard tissues of the jaw 
and the implant surface.  With the evolution of macrostructure, micro- and eventually 
nanotopography, osseointegration has become increasingly predictable, even in patients 
with systemic conditions(133).  Osseointegration is not without failures; in some cases 
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there are local and systemic factors play a role in the formation and maintenance of this 
structural and functional relationship between the implant surface and bone(7, 97).  Once 
implant success became more predictable, the focus then shifted to hastening the process 
and inducing a more vigorous osseointegration response in healthy and patients 
predisposed to implant failure.  The introduction of porous tantalum trabecular metal 
(PTTM) was utilized during orthopedic implants as an alternative to titanium due to its 
biologic response and ability to be formed in porous three-dimensional open cell structures 
to facilitate enhanced bone ingrowth(124, 132).  The designed porosity allows for its 
enhanced osteoconduction and angiogenesis, permitting bone to actually anchor onto the 
outer surface and inside the interconnected pores of PTTM, characterized as 
“osseoincorporation”(119, 130, 134, 135).   PTTM has recently crossed over to use in the 
oral cavity to replicate the hard tissue response seen in orthopedic implants(119, 136).  
Tantalum was selected as an alternative to titanium due to its modulus of elasticity that is 
similar to trabecular bone and its resistance to corrosion coupled with improved frictional 
properties(121, 125, 126).   However, it is similar to titanium with concern to the 
biocompatibility, biochemical and biomechanical properties that support 
osseointegration(125, 126).  What continues to warrant further investigation is whether 
PTTM implants are able to more robustly induce osseointegration in patients with risk 
factors that compromise bone remodeling.  
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CHAPTER 2: OSTEOGENIC ACTIVITY ASSOCIATED WITH DENTAL IMPLANT 
PLACEMENT IN PATIENTS WITH OSTEOPENIA/OSTEOPOROSIS AS 
COMPARED TO HEALTHY INDIVIDUALS 
 
Introduction 
 The implementation of dental implants for the treatment of partial and fully 
edentulous patients has evolved through the years and become common practice throughout 
the world.  Dental implant therapy is considered an effective, safe and reliable method of 
treatment that is a viable alternative to conventional fixed and removable prostheses.  
Regardless of the documented predictability, failures still occur and patients with certain 
behavioral and systemic conditions are at increased risk of failure(8).  The predictability of 
dental implant therapy is predicated on the ability to achieve and maintain intimate contact 
with the alveolar bone that is both a functional and structural relationship, known as 
osseointegration(137, 138).  The gold standard for determining the success and degree of 
osseointegration is histology, however, this is not a viable option clinical practice(139).  
Therefore, the success of osseointegration has been defined by a lack of increasing mobility 
between the implant and the surrounding trabecular bone after implant placement(83).   
   Throughout the years, research has been done to investigate the complex pathways 
involved in bone healing in vivo, however the minutia involved in these signaling 
pathways has not been fully elucidated(140).  While research has teased apart the major 
pathways involved in osseointegration of healthy patients, even less is known about
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intricate interaction of pathways involved in osseointegration in vivo medically 
compromised patients(22, 141).   
With the introduction of new biomaterials, such as PTTM, their ability to aid in 
more efficient osseointegration, not only in healthy but medically compromised patients is 
currently being researched(142).    
Section 2.1 Methods and Materials  
Clinical Relevance 
Porous tantalum trabecular metal (PTTM) may enhance initial implant healing in the oral 
cavity as shown in orthopedic implant studies and therefore may be indicated for early 
implant loading and restoration in healthy subjects.  PTTM may also be useful for subjects 
with compromised bone healing or density; however, future studies are needed for 
compromised healing population.  The primary aim of the study was to examine whether or 
not the PTTM can improve bone ingrowth, thereby increasing the bone to implant contact 
(BIC).  It was theorized that the micro porous structure would induce earlier bone deposition 
around implants when compared to conventional titanium (Ti) alloy, leading to more robust 
osseointegration.  
Participants 
 This study was approved by the Biomedical Institutional Review Board of the 
University of North Carolina at Chapel Hill, IRB:11-2539.  Written informed consent was 
obtained from all study participants. The study population consisted of 13 adults in adequate 
periodontal health that were eligible and treatment-planned to receive mandibular dental 
implants. One subject was withdrawn due to insufficient alveolar bone.  Subjects with 
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symmetrical edentulous areas in the mandible, requiring placement of at least 4 implants, 
were recruited through UNC and its healthcare system.   The control group for the histologic 
arm of the study consisted of 6 systemically healthy individuals, and the experimental group 
consisted of 6 patients with osteoporosis, diagnosed previously by a physician.   Major 
exclusion criteria included: use of medications known to affect periodontal status within one 
month prior to initial examination, systemic conditions that are known to affect periodontal 
status, history of IV bisphosphonates, active infectious disease, pregnancy, current smokers 
or history of smoking within the last two years, subjects with blood disorders and/or 
anticoagulant therapy, chemotherapy, and radiotherapy.   Specific inclusion and exclusion 
criteria are shown in Figure 2.1.  
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Figure	2.1	Inclusion	and	Exclusion	Criteria	
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The included subjects’ demographic information is shown in Table 2.1. 
 
 	
Demographics Healthy 
Osteopenia/ 
Osteoporosis 
N=12 6 6 
Age 64.3±6.0 66.38±5.15 
Male 4 0 
Female 2 6 
Caucasian 5 5 
African American 1 1 
Cross Sectional 
Processing 
2 3 
Longitudinal 
Processing 
4 3 
	
Table	2.1:	Patient	Demographics 
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 An edentulous ridge area with sufficient space to place two test cylinders (each 
approximately 2.9-3 x 5 mm) was confirmed radiographically.  Patients had a CBCT taken 
with a radiographic stent to confirm adequate alveolar dimension.  For each patient, two 
titanium test cylinders were placed on the mandible at the level of the crestal bone and 
covered with a collagen membrane (BioMend, Zimmer Dental, Carlsbad, CA, USA) to 
prevent soft tissue down growth, primary closure was obtained. Test cylinders were removed 
at two and four weeks using a 5.0 mm diameter tissue punch and 4.5mm trephine drill and 
sites received a screw vent implant (Zimmer Dental, Carlsbad, CA, USA), upon the removal 
of the test cylinder.  
Study design 
Each subject was screened clinically and radiographically. Cone-beam computed tomography 
(CBCT) scans were used to examine the pre-existing alveolar bone.  The CBCT scans were 
reviewed by one of the implant surgeon investigators (SB or TM).  Simplant 16 (Dentsply, 
York, PA) or 360dps implant planning software (360imaging, Atlanta, GA) was used to 
determine if there was sufficient bone for future dental implant therapy. A minimal width of 
7mm and height of 8mm for each dental implant was required for inclusion into the study. 
The minimal bone volume was needed to ensure that the 3mm x 5mm diameter device could 
be placed, preventing bone dehiscence or approximating any anatomical structures.  At each 
surgical visit, subjects were asked to rinse their mouth with 0.12% Chlorhexidine gluconate 
prior to any procedure.  All surgical procedures were completed under local anesthetics 
involving bilateral inferior alveolar nerve blocks, long buccal nerve blocks and local 
infiltration of the surgical sites.  Full thickness flaps were raised in all sites. A split-mouth 
design was used. Four osteotomy sites were located and prepared based on the pre-operative 
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CBCT scans, implant planning software, and a surgical guide. Two 3mm x 5mm Ti alloy 
tapered screw and two 3mm x 5mm PTTM cylinder devices were placed in each edentulous 
site, Ti test cylinders on one edentulous side of the jaw and PTTM test cylinders on the other 
as seen in Figure 2.2 and 2.3.   
	
Figure	2.2:	Ti	and	PTTM	Test	Cylinders.	(Photo	courtesy	of	Dr.	Thiago	Morelli). 
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Figure	2.3:	Test	cylinders	immediately	after	insertion,	right	photo	is	PTTM	test	cylinders,	left	photo	is	Ti	test	
cylinders	in	the	same	patient.	(Photo	courtesy	of	Dr.	Thiago	Morelli). 
The top of each test cylinder was placed at the level of crestal bone level to ensure that the 
device was completely surrounded by bone. Note that since the Ti device was a self-tapping 
tapered screw, a 2.3 mm drill was used and the Ti device was self-tapped in place.  Ti device 
also has HA blasted surface treatment mimicking the clinically used and commercially 
available dental implants (MTX, Zimmer Biomet, Palm Beach Garden, FL). However, since 
the PTTM device was a straight cylinder, a 3 mm drill was used to place the device. The 
PTTM device was press-fitted in place.  A 5 mm diameter resorbable collagen membrane 
(Biomend, Zimmer Biomet, Warsaw, IN) was placed on top of each device. A combination 
of continuous interlocking and interrupted suturing techniques with 4.0 chromic gut sutures 
were used to ensure the primary closure and hemostasis. The subjects were instructed to 
continue using a 0.12% Chlorhexidine rinse until the completion of the study (a total of about 
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6 weeks, 2 weeks more after the final surgery). One device from each group was removed 
using 4.5 mm diameter trephine drill (Salvin Dental Specialties, Charlotte, NC).   One device 
was from each metal type (PTTM or Ti) were removed at two weeks for non-histological 
analysis (data not reported as part of this thesis). Remaining test cylinder samples were 
explanted at the 4-week visit for histological analysis from both the healthy and osteopenia 
patient samples for both metal types (PTTM or Ti).  Histology was only evaluated in half of 
the samples collected at 4 weeks.  Histological analysis was only completed at the 4 week 
time point as any early, such as the 2 week time point would not have yielded sufficient 
mineralized tissue.  The explantation, through the use of the trephine, was completed in 
conjunction with a surgical guide, individually fabricated for each patient, the surgical guide 
with trephine can be seen in figure 2.4.  After explantation, each cylinder was placed 
separately into a microfuge tube containing 4% paraformaldehyde.  Test cylinders used for 
histologic analysis were processed properly (sample processing is described below). 
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Figure	2.4:	Trephine	with	stent.	(Photo	courtesy	of	Dr.	Thiago	Morelli). 
 
After each device removal, the osteotomy site was prepared for the definitive implant. 
Conventional titanium Tapered Screw Vent (TSV) implants (Zimmer Biomet, Warsaw, IN) 
were placed at each site. Bone allograft, Puros Cancellous Particulate (Zimmer Biomet, 
Warsaw, IN), and appropriate resorbable collagen membrane such as Biomend (Zimmer 
Biomet, Warsaw, IN) were used as needed if there was bone dehiscence around the dental 
implant. The subjects were then seen at least one more time 2 weeks after the removal of the 
final devices and placement of definitive dental implants. After the clinical operator 
determined that the subjects had appropriate soft tissue healing, subjects then exited the study 
and were referred back to their restorative providers to fabricate appropriate definitive 
prostheses. 
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Histology  
 Raw histologic samples comprised of tissue blocks from the test cylinders were 
prepared for ground sectioning utilizing the following methods. After explantation, each 
cylinder was placed separately into a microfuge tube containing 4% paraformaldehyde, then 
transferred to 0.1M Cacodylate buffer, pH 7.4, for several hours to overnight. Dehydration 
was started with an ethanol series: 50%, 70%, 95% ethanol in distilled water for 10 min each. 
They were then transferred into absolute ethanol for two rinses of 20 min each.  The samples 
were infiltrated with a 50:50 mixture of Polybed resin (Polysciences Inc, Warrenton, PA) and 
absolute ethanol for 6-12 hours. They were then embedded with several changes of pure resin 
into BEEM® capsules and cured overnight at 65 degrees Celsius.  The orientation of the 
samples during embedment was carefully maintained to facilitate cross-sectional or 
longitudinal slicing of the implant samples.  Cured resin blocks containing the implants were 
removed from the polyethylene capsules and were sectioned following the long axis or short 
axis of the implants using a Buehler diamond band saw fitted in a precision slicing machine 
(IsoMet® Low Speed Saw; Buehler; Lake Bluff, IL) with a thickness of approximately 50–
60µm.  Histological slides were stained with toluidine blue and examined under confocal 
microscope (Olympus® IX81) using bright field (BF) technique.   Histological images were 
taken using image analysis software (Volocity; PerkinElmer®, Waltham, MA) taking stacks 
of images up to 30 separately focused stacks for each slice.  Images were taken at a 
magnification of 4x and 20x.   Due to the three dimensional structure of the trabecular test 
cylinders that required the use of image stacking, an image processing program was utilized 
to stitch stacked images together utilizing the software ImageJ (developed by the NIH).   The 
use of digital refocusing with extended depth of field (EDF) plugin was utilized to complete 
	 44	
and merge focus stacking from different focal positions, providing an entirely focused 
composite image.  Composite images were then analyzed in ImageJ to calculate BIC 
percentage. 
 Histologic samples were randomly assigned to be processed in one of two methods, 
cross sectional or longitudinal processing.  A total of 6 patients, 4 healthy control and 2 
experimental (osteopenia/osteoporosis) were sectioned longitudinally and analyzed for 
surface area, BIC percentage and total BIC. 
Section 2.2 Statistical Analysis  
 A general linear model (GLM); a type of ANOVA, utilizing a least squares regression 
approach to analyze both BIC percentage and BIC total comparing the different combinations 
of metal (titanium and PTTM) and patient type (healthy and osteopenia/osteoporosis), 
utilizing SAS software.  A General estimating equations (GEE) model was used to control 
for the repeated measures within subject at one time point for the different metal types (Ti or 
PTTM).  Level of significance was set at 0.05. 
 Differences within individuals patients also know as change scores were analyzed 
using a T-test within subject to analyze the BIC percentage change and the total BIC for the 
different test cylinder metal types (PTTM vs Ti).   Level of significance was set at 0.05. 
Section 2.3 Results  
 Four osteopenic/osteoporotic female subjects aged between 59 to 76 years were 
included in this study.   Six healthy male and female subjects aged 54 to 71 were included in 
this study.  A total of 20 experimental cylinders (n = 10 Ti control cylinders and 10 PTTM 
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test cylinders) were placed.  Each subject received 2 adjacent test cylinders and 2 adjacent 
control cylinders on opposites sides of the same jaw.  At each time point, one Ti and one 
PTTM test cylinder were retrieved from each subject.  Cylinders retrieved at the 4-week time 
point were randomly selected for histologic evaluation or genetic profiling.  Comparisons 
were performed to analyze PTTM cylinders to the Ti cylinders in osteopenic/osteoporotic 
patients at 4-week time points as well as osteopenia/osteoporosis patients to healthy control 
patients. 
Histology 
 Histological evaluation was the method used to determine if there was increased BIC 
between the two materials/microstructures.  Longitudinal and cross sectional analyses were 
performed for subjects in the control and experimental groups.  Longitudinal sectioning was 
utilized to calculate the BIC percentage, total and surface area, while cross sectional was 
utilized to qualitatively evaluate the bone ingrowth and penetration into the PTTM.  While 
cross sectional slicing was utilized to qualitatively evaluate the bone ingrowth and 
penetration into the PTTM test cylinders in direct comparison to the Ti test cylinders. 
Comparison of 4x magnification of Healthy (Ti and PTTM) to Osteopenia/Osteoporosis (Ti 
and Ta) 4x magnification was completed and analyzed, Figure 2.5 and Figure 2.7.  The BIC 
total and BIC percentages were not calculated for the cross sectional histological slices.   BIC 
was calculated as a percentage and as a total, both of which were analyzed for statistical 
significance.  Two patients from the experimental (Osteoporosis/osteopenia group) and two 
patients from the control (healthy group) were utilized for cross sectional qualitative 
evaluation.    
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Comparison of 20x magnification of Healthy (Ti and Ta) to Osteopenia/Osteoporosis (Ti and 
Ta) 20x magnification was completed and analyzed, Figure 2.6 and Figure 2.8.   
Figure	2.5:	Histology	4x	Tantalum	(a)	and	Titanium	(b)	test	cylinders	in	healthy	patients.	 
a.	 b..	
Figure	2.6:	Histology	4x	Tantalum	(a)	and	Titanium	(b)	test	cylinders	in	osteonpenia/osteoporotic	patients. 
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Cross sectional cuts were made from selected subjects to visualize the depth of bone 
penetration.  Examples of the cross sectional comparison at 4x is seen in Figure 2.9.   
Figure	2.7:	Histology	20x	Tantalum	(a)	and	Titanium	(b)	test	cylinders	in	healthy	patients.  
a.	 b.	
a.	 b.	
Figure	2.8:	Histology	20x	Tantalum	(a)	and	Titanium	(b)	test	cylinders	of		osteopenia/osteoporotic	patients. 
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Figure	2.9:	Cross-sectional	slices	of	Titanium	(left),	and	PTTM	(right)	test	cylinders. 
 
Graphical representation of statistical comparison of mean BIC percentage can be seen in.  
Figure 2.9 and Table 2.2 and 2.3, while mean total BIC can be seen in Figure 2.11 and Table 
2.4 and 2.5.   BIC was calculated as a percentage, by calculating the surface area of test 
cylinder for the selected field of view, then the bone in direct contact with the implant was 
calculated and a percentage was obtained.  The total BIC was calculated based on the total 
bone in contact with the test cylinder surface, irrespective of surface area.  All calculations 
utilized the longitudinal samples for quantitative analysis, however, the cross sectional slices 
were utilized for qualitative evaluation.   
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Figure	2.10:		GLM	Analysis	of	BIC	mean	percentage	(%).		Comparison	completed	between	healthy	and	
osteopenia/osteoporosis	and	titanium	and	tantalum.		Solid	colors	represent	healthy,	diagonal	lines	
represent	osteopenia/osteoporosis.		Blue	represents	Titanium	and	green	represents	PTTM.	*	represents	
statistical	significance	(P=	<0.05) 
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Group Type Metal Type BIC Mean Percentage  
Standard 
Error 
Healthy Titanium 19.0 ±5.0 
Healthy Trabecular 
(PTTM) 
11.0 ±3.5 
Osteopenia Titanium 26.0 ±5.0 
Osteopenia Trabecular 
(PTTM) 
21.9 ±5.0 
Table	2.2:		GLM	Analysis	of	BIC	mean	percentage	(%).		Comparison	completed	between	healthy	and	
osteopenia/osteoporosis	and	titanium	and	tantalum.		Level	of	significance	set	at	(P=	<0.05).		Statistical	
significance	found	comparing	Osteopenia/Osteoporosis	titanium	to	Healthy	trabecular	subjects.	No	other	
statistical	difference	was	noted.															
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Parameter Estimate Standard Error 95% 
Confidence 
Limits 
P Value 
Titanium 5.9 1.5 2.9 - 8.8 0.001 
Osteopenia 10.9 3.4 4.3 - 17.6 0.0012 
Osteopenia 
Titanium 
-1.8 1.4 -4.9 - 1.1 0.23 
Table	2.3:	Analysis	of	GEE	Parameter	Estimates	for	Mean	BIC	Percentage,	Empirical	Standard	Error	
Estimates.	
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Figure	2.11:	GLM	Analysis	of	BIC	mean	total.		Comparison	completed	between	healthy	and	
osteopenia/osteoporosis	and	titanium	and	tantalum.		Solid	colors	represent	healthy,	diagonal	lines	
represent	osteopenia/osteoporosis.		Blue	represents	Titanium	and	green	represents	PTTM													
	 53	
Group Type Metal Type BIC Mean Total Standard Error 
Healthy Titanium 197.5 ±76.4 
Healthy Trabecular 
(PTTM) 
203.2 ±54.0 
Osteopenia Titanium 263.2 ±76.4 
Osteopenia Trabecular 
(PTTM) 
321.6 ±76.4 
Table	2.4:		GLM	Analysis	of	BIC	mean	total.		Comparison	completed	between	healthy	and	
osteopenia/osteoporosis	and	titanium	and	tantalum.		 		
Parameter Estimate Standard 
Error 
95% 
Confidence 
P Value 
Titanium -58.5 28.5 -114.3 - -2.6 0.04 
Osteopenia 65.7 94.2 -118.9 - 250.4 .4856 
Osteopenia 
Titanium 
0.07 31.8 -62.2 - 62.4 0.9 
Table	2.5:	Analysis	of	GEE	Parameter	Estimates	for	Mean	Total	BIC,	Empirical	Standard	Error	Estimates.		
The difference within patient samples, comparing the different metals was calculated using a 
change score and analyzed for significance utilizing a t-test.  Mean difference for BIC 
percentage, Total BIC and total surface area were calculated. Mean difference BIC 
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Percentage can be seen in Figure 2.12.  While mean difference total BIC can be seen in 
figure 2.13 and mean difference of surface area can be seen in figure 2.14.  
	
Figure	2.12:	Mean	difference	in	BIC	percentage	within	individual	patients	comparing	PTTM	vs	Ti.		Green	is	
osteopenia,	blue	is	healthy.					
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Figure	2.13:		Mean	difference	of	total	BIC	within	individual	patients	comparing	PTTM	vs	Ti.		Green	is	
osteopenia,	blue	is	healthy 
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Figure	2.14:		Mean	difference	of	total	surface	area	within	individual	patients	comparing	PTTM	vs	Ti.		Green	is	
osteopenia,	blue	is	healthy 
 There was not a statistically significant difference between the titanium or PTTM test 
cylinders for either group (healthy or osteopenia/osteoporosis) of patients, when comparing 
means for BIC percentage, total BIC or surface area P value= >0.05.  A trend was seen 
during the analysis of the surface area in favor of the PTTM, however, no statistical 
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difference was noted between the healthy vs experimental groups.  No statistical difference 
was found between the experimental or healthy group, or between the titanium and PTTM 
group except when comparing the healthy titanium to the osteopenia/osteoporosis PTTM 
group, P=<0.05.  With the GEE model for the BIC percentage comparison, Ti test cylinders 
showed a significantly higher percentage of BIC compare to PTTM test cylinders, in 
addition, osteopenia/osteoporosis patients showed a significantly higher percentage of bone 
to implant contact compared to healthy patients.  Once again the interaction between metal 
type and disease/health status was not significant. Utilizing the GEE model for BIC total 
comparison, Ti test cylinders showed a significantly reduced amount of total bone contact 
compared to PTTM test cylinders, while Osteopenia/osteoporosis patients showed and 
increased amount of total bone contact with either metal compared to healthy patients. Once 
again the interaction between metal type and disease/health status was not significant.   
Discussion 
 At present, the most commonly used material for the use of dental implants is medical 
grade titanium.  Titanium is so widely used due to its many properties that have shown long 
term clinical success; these include biocompatibility, biochemical and biomechanical 
properties(143).  Despite its many superior qualities, titanium displays less than ideal 
frictional properties and shear strength, along with a modulus of elasticity dissimilar to 
bone(143).  Titanium implants have been proved to have a reduced capability for 
osseointegration in systemically compromised patients(144, 145).  With millions of 
Americans affected by some sort of systemic disease and the aging population ever 
increasing, there is a push for improved biomaterials that have a quicker and more robust 
osseointegration in healthy as well as medically compromised patients.  PTTM appears to be 
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a viable alternative to traditional titanium implant, providing increased mechanical retention 
and a microstructure that resembles cancellous bone(125).  Tantalum has several advantages 
over conventional titanium implants, some of which include strength, high porosity, and high 
coefficient of friction(124).  It is these characteristics that have brought it to the forefront of 
implant dentistry after the results from orthopedic implant studies.      	 Histological	analysis	via	bone	to	implant	contact	both	as	a	percentage	and	a	total	was	utilized	to	analyze	histologic	samples.		Currently	the	gold	standard	for	research	based	evaluation	of	implant	stability	is	histologic	evaluation	of	BIC	percentage(91).		This	gold	standard	was	used,	however,	BIC	total	was	also	calculated	due	to	the	morphology	of	the	PTTM,	which	drastically	increases	the	surface	area.		The	increased	surface	area	and	the	morphology	of	the	PTTM	material	allows	for	enhanced	clot	stabilization	and	lends	itself	increased	bone	to	implant	contact.		In	Figure	2.13	the	BIC	percentage	demonstrated	titanium	test	cylinders	had	increased	BIC.		This	data	may	over	estimate	the	amount	of	bone	present	due	to	the	decreased	surface	area	for	the	titanium	test	cylinders,	while	the	PTTM	test	cylinder	surface	area	was	drastically	increased.			The	timing	of	the	histological	sampling	may	have	contributed	to	the	limited	amount	of	bone	present	in	all	samples.		Previous	studies	have	shown	a	similar	BIC	percentage	to	those	found	in	our	study	for	titanium	implants	at	4	weeks,	however,	they	demonstrated	increased	BIC	percentage	when	analyzed	at	3	months(146).		Previous	studies	evaluating	dental	implant	healing	through	the	use	of	human	histology	retrieved	samples	at	a	6-week	time	point.		Moreover	in	histologic	samples	were	taken	retrieved	at	6	weeks	in	a	study	evaluating	implant	healing	in	type	IV	bone(147).	
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Furthermore	the	three	dimensional	structure	made	obtaining	a	crisp	and	completely	focused	image	difficult	and	required	the	use	of	imaging	software	to	splice	together	multiple	slices.		These	multiple	slices	may	have	had	focus	on	the	PTTM	structure	rather	than	the	osseous	structure,	which	would	have	revealed	more	osseous	contact.		In	addition	to	previously	mentioned	factors,	small	sample	size,	especially	in	the	disease	group	may	have	been	a	contributing	factor	for	the	lack	of	significance.		A	larger	sample	size	would	also	provide	more	power	to	detect	differences	between	the	groups.		 In	addition	to	sample	size	and	timing	of	histological	sampling,	the	use	of	oral	bisphosphonate	therapy	may	have	acted	as	a	confounding	factor	in	histologic	samples.			Bisphosphonates	inhibit	osteoclast	function,	this	inhibition	favors	bone	formation	and	in	turn	promote	increase	bone	mineral	and	density(62).		Animal	models	show	that	systemic	treatment	with	bisphosphonates	can	increase	new	bone	formation	around	dental	implants(148).		A	requirement	for	inclusion	in	the	study	was	the	use	of	oral	bisphosphonates	to	confirm	the	diagnosis	of	osteopenia	or	osteoporosis,	this	may	have	inadvertently	created	a	confounding	factor	and	may	explain	the	trend	for	osteoporotic	patients	demonstrating	more	BIC	percentage	and	total	BIC	in	both	titanium	and	tantalum	test	cylinders.		Although	this	study	was	looking	at	early	osseous	healing	changes	in	relation	to	different	dental	implant	materials	in	healthy	and	osteoporotic	patients,	patients	taking	bisphosphonates	tend	not	to	have	complications	with	early	osseous	healing.		Recent	research	suggests	that	patients	taking	bisphosphonates	may	be	at	an	increased	risk	of	peri-implant	bone	loss	after	osseointegration	rather	than	implant	loss	resulting	from	osseointegration	failure(149).		This	suggests	that	the	mechanism	of	bisphosphonates	results	in	impaired	bone	remodeling	and	turnover	around	peri-
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implant	tissues,	resulting	in	high	risk	for	peri-implant	bone	loss	and	potentially	late	failures(149).				
Although not quantitatively analyzed, it was noted during histologic analysis that the 
distance between the old native bone and the PTTM test cylinder compared the threaded Ti 
test cylinder was larger.  This observation is due to the differences in osteotomy preparations 
for the test cylinder.  The conventional titanium threaded test cylinders could be under 
prepared and the threads would allow for an intimate fit of the threads to the old native bone.  
However, the PTTM test cylinder required exact osteotomy preparation due to lack of threads 
and the press fit nature of this particular test cylinder.  This distance of native bone to the 
implant surface may have been another confounding factor for the trend for BIC % favoring 
the conventional titanium.   
Overall the histologic data showed a no significant differences in comparing the two 
metals, with the exception of osteoporosis titanium test cylinder mean BIC % to that of 
healthy trabecular patients.  All other comparisons were not significant for mean BIC % and 
mean total BIC.  There was, however, a trend for increase bone formation in 
osteoporosis/osteopenia patient samples for both titanium and PTTM test cylinders.  The 
total BIC trended in favor of the PTTM, however the BIC % trended in favor of the Ti test 
cylinders.  The BIC % favored Ti due to the decreased surface area and the distance between 
native bone and the test cylinder surface.      
Aside from obtaining an insight in the human histologic analysis around 
conventional titanium implants and PTTM implants associated with osseous healing around 
dental implants in health and osteopenia/osteoporotic patients, it was concluded that patients 
with PTTM implants present important differences in osseous healing compared to animal 
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studies.  It was also determined that the evaluation of PTTM implants must be analyzed 
differently than conventional implants due to the different surface characteristics as well as 
distinctive initial bone contact.    These findings suggest that the critical events associated 
with bone formation during the process of osseointegration are influenced by the surface 
of the implant, and in particular by the cell– implant interface.  Compared to Ti, PTTM 
exhibited a more robust response towards early bone formation and mineralization, 
which may potentially enhance osseointegration.
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CHAPTER 3: CONCLUSION 
 Our results indicate that patients with osteopenia/osteoporosis demonstrated there were 
no significant differences in histologic osseous healing at 4 weeks between healthy and 
osteopenic/osteoporotic patients, and the literature demonstrates controversy as to whether 
these diseases affect osseous healing.  Histologic analysis revealed no statistical significance 
between the healthy and the osteopenia/osteoporosis group differences of BIC percemtage or 
total BIC at 4 weeks, however, a difference may be seen at a later time point or after 
remodeling is completed.   Although on initial evaluation no difference was found, much was 
learned about how to evaluate the two different surfaces/metals in the future.  PTTM 
morphologically has the ability for enhanced clot stability and displayed osteoid structures 
penetrating within the porous structure.  This osseous penetration could allow for increased 
osseointegration and implant stability.  With several other systemic conditions that could 
affect osseous healing around implants, PTTM demonstrates a potential alternative option for 
conventional implant therapy due to up-regulation of specific genes involved in osseous 
healing.  The clinical implications of this study are that better understanding of the process of 
osseointegration can lead to improved treatment strategies by targeting pathways involved 
early on in the process.  It will also allow for the incorporation of PTTM in conventional 
dental implant therapy and further promote early osseointegration.  This can be completed 
through the use of novel biomaterials or mimicking three dimensional organic 
macrostructures, leading to improved treatment strategies aimed at enhancing 
osseointegration and long term success of dental implants in healthy individuals and patients 
	 63	
with osteoporosis.  Further research is needed to better evaluate histologic analysis of healing 
at a later time point with supplementation with molecular data to confirm if PTTM induces a 
more robust early osseointegration.  
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